Aktis Oncology (AKTS) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Adjusted EPS
- -$0.44
- Estimate
- -$0.43
- Surprise
- -2.1%
- Revenue (period 2026-06-30)
- $3.4M
- Score today
- 5.8/10
Revenue source: xbrl.
How the report landed
Aktis Oncology (AKTS) reported a wider loss than forecast — adjusted EPS of -$0.44 against the -$0.43 estimate (a 2.1% shortfall).
Coverage in the report window
- Micron and 15 Other Stocks To Play The AI Buildout Race: They Are Still 20% Below Highs — benzinga, 2026-08-14
- Aktis Oncology Q2 EPS $(0.44) Misses $(0.43) Estimate, Sales $3.384M Beat $2.000M Estimate — benzinga, 2026-08-13
Where TrendMatrix's rating stands now
TrendMatrix currently rates AKTS Sell at 5.8/10; no pre/post engine snapshot brackets this report.
1 of the last 4 quarters beat the estimate; this quarter's -2.1% surprise compares with a -99.8% four-quarter average. Next scheduled report: 2026-11-12.
What argues against it
- Concentration risk — Pipeline: lead product candidate [225Ac]Ac-AKY-1189
- Quality below floor (3.4 < 4.0)
- Value-trap signals (2/5): Margin compression (op margin 3.2%), Material insider selling (6 sells, 0.92% of cap)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $19.72
- Price target
- $30.79
- Stop
- $19.08
- Upside to target
- +56.1%
- Reward-to-risk
- 3.8:1
Risk check: RSI 15 — a level conventionally read as oversold.
Model outputs from TrendMatrix’s engine as of 2026-09-24 — shown for context, not personalized investment advice.
AKTS at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $1.10B
- P/E (fwd)
- -9.2
- 52-week range
- $14.72–$34.19
- Off 52-week high
- 42.3%
- RSI (14)
- 15
- Volume vs avg
- 1.25×
- Score today
- 5.8/10